Tier 1 — highest

Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems: A randomized controlled trial

Heather A Hausenblas, Tarah Lynch, Stephanie Hooper, Aahana Shrestha, Doug Rosendale, Jennifer Gu
Sleep medicine: X 2024 8:100121

Bibliography

PubMed
PMID 39252819
PubMed Central
PMC11381753
DOI
10.1016/j.sleepx.2024.100121
Funding
The trial reports support from AIDP Inc. See the original publication and accompanying corrigendum for funding and disclosure details.
Competing interests
AIDP funded the study. The accessible source includes a competing-interest declaration and an additional financial-disclosure statement; consult the original publication for the complete context.

Study snapshot

DesignRandomized, double-blind, placebo-controlled trial
ModelHuman participants
Sample80 adults aged 35–55 with self-reported sleep problems
InterventionMagnesium L-threonate 1 g/day or placebo
Duration21 days
EndpointsSleep questionnaires; Oura wearable sleep metrics; Daytime function and mood

What the study showed, in plain terms

This publication examines sleep questionnaires, oura wearable sleep metrics, daytime function and mood. Study population or evidence base: 80 adults aged 35–55 with self-reported sleep problems. Intervention or exposure: Magnesium L-threonate 1 g/day or placebo.

Key findings

Selected wearable sleep scores and subjective measures of waking behavior, energy and daytime function favored magnesium L-threonate.

What this study can and cannot tell us

Short trial with multiple outcomes and consumer-wearable measures, rather than polysomnography. The findings apply to the tested 1 g/day regimen and selected sleep complaints.

A corrigendum published in 2025 accompanies the original report and should be considered when reviewing it.

Related papers in the corpus

Tier 1
Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
Guosong Liu et al. · Journal of Alzheimer's disease : JAD · 2016
Tier 1
A Magtein®, Magnesium L-Threonate, -Based Formula Improves Brain Cognitive Functions in Healthy Chinese Adults
Chengxiang Zhang et al. · Nutrients · 2022
Tier 1
The effects of magnesium L-threonate (Magtein®) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial
Adrian L Lopresti et al. · Frontiers in nutrition · 2026
Tier 1
Oral application of magnesium-L-threonate enhances analgesia and reduces the dosage of opioids needed in advanced cancer patients-A randomized, double-blind, placebo-controlled trial
Siyin Wu et al. · Cancer medicine · 2023
Tier 1
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Therapeutic Effect of Magnesium-L-Threonate Supplementation for Persistent Pain After Breast Cancer Surgery
Yuncheng Ni et al. · Breast cancer (Dove Medical Press) · 2023
Tier 3
Enhancement of learning and memory by elevating brain magnesium
Inna Slutsky et al. · Neuron · 2010

Citation network

Articles citing this research paper

7 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Biohack Blueprint Research